104 results
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
to the agreement. No litigation or the triggering of other dispute mechanisms has been entered into by either party, and the Company's management is actively
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
. If the Company becomes involved in patent litigation, it could consume a substantial portion of its resources.
- 22 -
The Company may be subject … in the execution of the duties of such officers or directors. Such limitations on liability may reduce the likelihood of derivative litigation against
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
the existence of such a breach and insists on the ongoing validity of the respective obligations of both parties pursuant to the agreement. No litigation
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
of the affected technology. If the Company becomes involved in patent litigation, it could consume a substantial portion of its resources.
- 22 … litigation against the Company's officers and directors and may discourage or deter its shareholders from suing the Company's officers and directors based
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Aug 23
Notice of Annual General and Special Meeting of Shareholders
5:15pm
) judgments entered or settlements reached in litigation;
(ii) the write-down of assets;
(iii) the impact of any reorganization or restructuring;
(iv
6-K
EX-99.2
zy0 0o879
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
6-K
EX-99.1
qebc5qh dgz
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
6-K
EX-99.2
0zl84azgl6
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
6-K
EX-99.5
6k9b5dbk
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
6-K
EX-99.1
vyrz h7jtqu3nnnlwe4
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
20-F/A
p0ai4cwz2b
12 Sep 22
Annual report (foreign) (amended)
6:17pm
6-K
EX-99.2
5mai8
6 Sep 22
Condensed Consolidated Interim Financial Statements
12:42pm
6-K
EX-99.1
ew307ym
6 Sep 22
Condensed Consolidated Interim Financial Statements
12:42pm
6-K
EX-99.3
jwv kvvji
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.4
g0pbrevikh
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.1
vdlce5
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
EX-99.2
kh6hoq6t4j9x5lsk
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
EX-99.2
xh9uagaaab12 gbtrdz
31 Aug 21
Condensed Consolidated Interim Financial Statements
1:45pm